Brokerage firm Canaccord Genuity Upgrades its rating on Agios Pharmaceuticals Inc(NASDAQ:AGIO). In a research note issued to the investors, the brokerage major Raises the price-target to $90.00 per share. The shares have been rated Buy. Previously, the analysts had a Hold rating on the shares. The rating by Canaccord Genuity was issued on Jun 13, 2016.
In a different note, On May 18, 2016, Credit Suisse said it Maintains its rating on Agios Pharmaceuticals Inc. In the research note, the firm Raises the price-target to $65.00 per share. The shares have been rated ‘Outperform’ by the firm. SunTrust Robinson Humphrey said it Initiates Coverage on Agios Pharmaceuticals Inc, according to a research note issued on Mar 30, 2016. The shares have been rated ‘Buy’ by the firm.
Agios Pharmaceuticals Inc (AGIO) shares turned negative on Fridays trading session with the shares closing down -1.34 points or -2.74% at a volume of 10,45,417. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $49.74. The peak price level was also seen at $49.74 while the days lowest was $47.25. Finally the shares closed at $47.48. The 52-week high of the shares is $120.96 while the 52-week low is $33.5. According to the latest information available, the market cap of the company is $1,801 M.
Agios Pharmaceuticals Inc(AGIO) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $31.28M. Analysts had an estimated revenue of $20.94M. Earnings per share were $-0.61. Analysts had estimated an EPS of $-0.79.
Several Insider Transactions has been reported to the SEC. On Jun 10, 2016, Scott Biller (Chief Scientific Officer) sold 27,500 shares at $65.00 per share price.Also, On May 27, 2016, Lewis Clayton Jr. Cantley (director) sold 2,504 shares at $51.69 per share price.On Dec 17, 2015, John Duncan Higgons (Chief Operating Officer) sold 20,000 shares at $50.09 per share price, according to the Form-4 filing with the securities and exchange commission.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.